Dirucotide Does Not Meet Primary Endpoint In Phase III MAESTRO-01 Trial In Secondary Progressive Multiple Sclerosis
Links shared publicly online about this topic.
- 1,865total visits
Dirucotide Does Not Meet Primary Endpoint In Phase III MAESTRO-01 Trial In Secondary Progressive Multiple Sclerosis
Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disabi
View full resource at medicalnewstoday.com
Tags: Multiple Sclerosis, Disease and Condition, Eli Lilly and Company
Most Recently Shared on July 28, 2009 at 11:34 am By:
MedNewsToday: Dirucotide Does Not Meet Primary Endpoint In Phase III MAESTRO-01 Trial In Secondary .. http://bit.ly/LFi98
Eli Lilly and Company - Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
newsroom.lilly.com — “Eli Lilly and Company - Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis” View full resource at newsroom.lilly.com
Most Recently Shared on July 29, 2009 at 1:59 pm By:
eyeonfda Pharma and Health Lawyer
Lilly - Dirucotide Doesn't Meet Primary Endpoint in Phase 3 MAESTRO-01 Trial in 2dary Progressive MS http://bit.ly/wqQuh
Advertisement
